About Adequan® I.M.

Making strides for mobility.

Over the past 30 years, Adequan® I.M. (polysulfated glycosaminoglycan) has been recommended millions of times1 to treat degenerative joint disease (DJD) in horses, and with good reason. Since U.S. FDA-approval in 1989, it’s been the only approved equine PSGAG available, and the only one proven to: 2,3

  • Reduce inflammation
  • Restore synovial joint lubrication
  • Repair joint cartilage
  • Reverse the disease process
Adequan Equine horse legs running dust HR

There's nothing else like it.

Understanding the difference between the many therapeutic options for DJD can make a real difference in a horse’s long-term joint health.

By reviewing the choices together, the horse owner and veterinarian can consider the treatment options available and decide the best course of action.

It’s important to talk with your veterinarian to discover if Adequan® I.M. is the right treatment for your horse.

Rx Pyramid

Because mobility matters.

Mobility is a vital component to every horse’s health and well-being, so taking a proactive approach to diagnosis and treatment through each stage of life can help extend their mobility span.4 When you start with Adequan® I.M. early and stay with it as needed, horses may enjoy greater mobility over a lifetime.5

Discover if Adequan® I.M. is the right choice.

Adequan Equine brown white horse legs on grass HR
Adequan® I.M. brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS
Adequan® I.M. is recommended for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.
IMPORTANT SAFETY INFORMATION
Adequan® I.M. is for veterinary use only. The prescribing information contains complete use information which includes dosing, contraindications, warnings and cautions. Always read, understand and follow label and use directions. PLEASE CONSULT the Full Prescribing Information.
1. Data on File, American Regent Animal Health, Inc.
2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
3. Adequan® I.M. Prescribing Information, Rev 03/2021C.
4. McFarlane D. "How to Establish a HealthCare Program for the Aging Horse in Equine Practice, " AAEP Proceedings, 62: 2016.
5. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
Animal Health Logo